Dr. Marc Hedrick, MD - CEO, Plus Therapeutics - Radiotherapeutics For Difficult-To-Treat CNS Cancers

Dr. Marc Hedrick, MD is President and CEO of Plus Therapeutics, Inc. ( https://plustherapeutics.com/ ), a U.S. clinical-stage pharmaceutical company, focused on developing innovative, targeted radiotherapeutics for adults and children with difficult-to-treat cancers of the central nervous system. The company’s lead programs focus on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), leveraging image-guided local beta radiation and targeted drug delivery to improve outcomes.

Additionally, Plus' subsidiary CNSide Diagnostics develops proprietary lab tests such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases.

Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc.  

Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA).  

Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.

Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

#MarcHedrick #PlusTherapeutics #Radiotherapeutics #Cancer #CentralNervousSystem #Glioblastoma #LeptomeningealMetastases #Rhenium #ConvectionEnhancedDelivery #Oncology #Theranostic #NanoliposomeTechnology #Radioembolization #AlginateMicrospheres#BMEDAChelation#CNSide #REYOBIQ #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research